IRIS
SANTORO, MARIA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 28.735
AS - Asia 6.021
EU - Europa 4.660
SA - Sud America 828
AF - Africa 162
Continente sconosciuto - Info sul continente non disponibili 12
OC - Oceania 4
Totale 40.422
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 28.321
SG - Singapore 3.147
IT - Italia 976
CN - Cina 913
BR - Brasile 668
RU - Federazione Russa 624
DE - Germania 590
HK - Hong Kong 505
SE - Svezia 410
VN - Vietnam 377
IE - Irlanda 352
BD - Bangladesh 348
FI - Finlandia 337
UA - Ucraina 310
CA - Canada 308
FR - Francia 286
KR - Corea 241
PL - Polonia 241
GB - Regno Unito 229
JP - Giappone 153
NL - Olanda 86
IN - India 65
MX - Messico 59
ID - Indonesia 58
AT - Austria 56
AR - Argentina 47
ZA - Sudafrica 46
IQ - Iraq 38
ES - Italia 37
BE - Belgio 27
EC - Ecuador 24
TR - Turchia 24
PH - Filippine 22
PK - Pakistan 22
CZ - Repubblica Ceca 20
CL - Cile 18
CO - Colombia 18
MA - Marocco 18
CM - Camerun 16
DZ - Algeria 16
VE - Venezuela 16
LT - Lituania 13
JM - Giamaica 12
JO - Giordania 12
KE - Kenya 12
SA - Arabia Saudita 12
CH - Svizzera 11
EG - Egitto 11
PY - Paraguay 11
RO - Romania 11
BG - Bulgaria 10
BO - Bolivia 10
EU - Europa 10
UZ - Uzbekistan 10
IL - Israele 8
IR - Iran 8
MY - Malesia 8
PE - Perù 8
AE - Emirati Arabi Uniti 7
UY - Uruguay 7
AO - Angola 6
DO - Repubblica Dominicana 6
GR - Grecia 6
HN - Honduras 6
TH - Thailandia 6
CR - Costa Rica 5
GH - Ghana 5
NP - Nepal 5
PT - Portogallo 5
TN - Tunisia 5
TW - Taiwan 5
AL - Albania 4
AZ - Azerbaigian 4
ET - Etiopia 4
HU - Ungheria 4
PA - Panama 4
TT - Trinidad e Tobago 4
CI - Costa d'Avorio 3
CY - Cipro 3
KZ - Kazakistan 3
LB - Libano 3
MN - Mongolia 3
NG - Nigeria 3
NI - Nicaragua 3
TZ - Tanzania 3
ZM - Zambia 3
AM - Armenia 2
AU - Australia 2
KG - Kirghizistan 2
LY - Libia 2
MD - Moldavia 2
MT - Malta 2
PR - Porto Rico 2
PS - Palestinian Territory 2
SC - Seychelles 2
SK - Slovacchia (Repubblica Slovacca) 2
TD - Ciad 2
UG - Uganda 2
A1 - Anonimo 1
A2 - ???statistics.table.value.countryCode.A2??? 1
Totale 40.397
Salva come PNG Salva come JPEG
Città #
Woodbridge 6.937
Wilmington 6.848
Houston 5.425
Singapore 1.725
Fairfield 891
Ashburn 770
San Jose 720
Chandler 551
Ann Arbor 508
Hong Kong 492
Seattle 395
Council Bluffs 380
Beijing 362
Dublin 320
Cambridge 306
Rome 302
Santa Clara 260
Jacksonville 255
New York 243
Helsinki 237
Medford 230
Los Angeles 221
Kraków 213
Dearborn 176
Dundas 164
The Dalles 159
Tokyo 135
Ho Chi Minh City 115
Lawrence 108
Moscow 108
Buffalo 101
Hanoi 97
Milan 86
Munich 86
Lauterbourg 78
Dallas 74
São Paulo 69
Orem 66
San Diego 62
Nuremberg 59
Toronto 53
Zhengzhou 53
London 52
Menlo Park 49
Jakarta 45
Chicago 41
Mülheim 41
North Bergen 40
Phoenix 40
Denver 33
Lappeenranta 31
Creede 30
Amsterdam 29
Frankfurt am Main 29
Atlanta 27
Boardman 27
Chennai 25
Falls Church 25
Montreal 25
Palermo 24
San Francisco 24
Columbus 23
Naples 23
Vienna 23
Colorado Springs 22
Warsaw 22
Johannesburg 21
Mexico City 21
Redondo Beach 21
Dong Ket 20
Stockholm 20
Brussels 19
Turin 19
Haiphong 18
Boston 17
Poplar 17
Rio de Janeiro 17
Florence 16
Guangzhou 16
Seoul 16
Baghdad 15
Belo Horizonte 15
Bologna 15
Brooklyn 15
Nanjing 14
Brno 13
Da Nang 13
Norwalk 13
Querétaro 13
Shenyang 13
Manchester 12
Palo Alto 12
Porto Alegre 12
Redwood City 12
Salt Lake City 12
University Park 12
Amman 11
Charlotte 11
Durban 11
Miami 11
Totale 31.703
Salva come PNG Salva come JPEG
Nome #
Is there any potential for first-line etravirine use? Analysis from a large data set of antiretroviral therapy-naive HIV-infected patients undergoing resistance test 599
Lower prevalence of drug resistance mutations at first-line virological failure to first-line therapy with atripla vs. tenofovirRemtricitabine/lamivudineRefavirenz administered on a multiple tablet therapy 578
HCV NS3 sequencing as a reliable and clinically useful tool for the assessment of genotype and resistance mutations for clinical samples with different HCV-RNA levels 577
Characterization and structural analysis of novel mutations in human immunodeficiency virus type 1 reverse transcriptase involved in the regulation of resistance to nonnucleoside inhibitors 535
The Genotypic False Positive Rate Determined by Population V3-Sequencing can Predict the Burden of X4 Quasispecies Detected by Pyrosequencing 534
The lowest X4 Geno2Pheno false-positive rate is associated with greater CD4 depletion in HIV-1 infected patients 515
Two different patterns of mutations are involved in the genotypic resistance score for atazanavir boosted versus unboosted by ritonavir in multiple failing patients 514
Comparative Analysis of Drug Resistance Among B and the Most Prevalent Non-B HIV Type 1 Subtypes (C, F, and CRF02_AG) in Italy 511
Comet assay and micronucleus test in circulating erythrocytes of Cyprinus carpio specimens exposed in situ to lake waters treated with disinfectants for potabilization 508
'Sentinel' mutations in standard population sequencing can predict the presence of HIV-1 reverse transcriptase major mutations detectable only by ultra-deep pyrosequencing 494
Drug-resistance development differs between HIV-1-infected patients failing first-line antiretroviral therapy containing nonnucleoside reverse transcriptase inhibitors with and without thymidine analogues 486
Viro-immunological response of drug-naive HIV-1-infected patients starting a first-line regimen with viraemia >500,000 copies/ml in clinical practice 482
Specific mutations in the C-terminus domain of HBV surface antigen significantly correlate with low level of serum HBV-DNA in patients with chronic HBV infection 477
Involvement of novel human immunodeficiency virus type 1 reverse transcriptase mutations in the regulation of resistance to nucleoside inhibitors 475
Comparative evaluation of subtyping tools for the surveillance of newly emerging HIV-1 strains 475
Viro-immunologic response to ritonavir-boosted or unboosted atazanavir in a large cohort of multiply treated patients: the CARe Study 475
Population dynamics of HIV-1 subtype B in a cohort of men-having-sex-with-men in Rome, Italy 471
Specific enfuvirtide-associated mutational pathways in HIV-1 Gp41 are significantly correlated with an increase in CD4(+) cell count, despite virological failure 471
The multifactorial pathways towards resistance to the cytosine analogues emtricitabine and lamivudine: Evidences from literature 469
Structural modifications induced by specific HIV-1 protease-compensatory mutations have an impact on the virological response to a first-line lopinavir/ritonavir-containing regimen 459
Performance evaluation of an in-house human immunodeficiency virus type-1 protease-reverse transcriptase genotyping assay in Cameroon 450
Different evolution of genotypic resistance profiles to emtricitabine versus lamivudine in tenofovir-containing regimens 446
Characterization of drug-resistance mutations in HIV type 1 isolates from drug-naive and ARV-treated patients in Bulgaria 445
Specific mutations in HIV-1 gp41 are associated with immunological success in HIV-1-infected patients receiving enfuvirtide treatment 444
'Sentinel' mutations in standard population sequencing can predict the presence of HIV-1 reverse transcriptase major mutations detectable only by ultra-deep pyrosequencing 443
Non-B HIV type 1 subtypes among men who have sex with men in Rome, Italy 441
Different evolution of genotypic resistance profiles to emtricitabine versus lamivudine in tenofovir-containing regimens. 441
Dynamics of NRTI resistance mutations during therapy interruption 441
A very low geno2pheno false positive rate is associated with poor viro-immunological response in drug-naïve patients starting a first-line HAART. 438
Docking Analysis and Resistance Evaluation of Clinically Relevant Mutations Associated with the HIV-1 Non-nucleoside Reverse Transcriptase Inhibitors Nevirapine, Efavirenz and Etravirine 435
Temporal characterization of drug resistance associated mutations in HIV-1 protease and reverse transcriptase in patients failing antiretroviral therapy 430
Characterization of drug resistance mutations in naive and ART-treated patients infected with HIV-1 in Yaounde, Cameroon 429
Molecular Epidemiology of HIV Type 1 CRF02_AG in Cameroon and African Patients Living in Italy 424
Virological response and resistance profile in HIV-1-infected patients starting darunavir-containing regimens 424
Circulation of HIV-1 CRF02_AG among MSM population in central Italy: a molecular epidemiology-based study 421
An update on integrase inhibitors: new opportunities for a personalized therapy? The NEXTaim Project 421
Genotypic resistance test in proviral DNA can identify resistance mutations never detected in historical genotypic test in patients with low level or undetectable HIV-RNA 421
High sequence conservation of human immunodeficiency virus type 1 reverse transcriptase under drug pressure despite the continuous appearance of mutations 418
Efficacy of etravirine combined with darunavir or other ritonavir-boosted protease inhibitors in HIV-1-infected patients: An observational study using pooled European cohort data 418
HIV-1 Drug Susceptibility to Potential Second- and Third-Line Antiretroviral Regimens among Cameroonian Patients: Evidence from a Cross-sectional Design 418
HIV-1 R5+ /X4- tropic viruses can be inhibited in vitro as well as in vivo by maraviroc: a refined analysis of patients enrolled in the Phase IIb study A4001029 417
Drug Resistance Among Drug-naive and First-line Antiretroviral Treatment-failing Children in Cameroon 415
Temporal change in the use of genotypic resistance testing over the years 1999--2003 409
Short communication: Population-based surveillance of HIV-1 drug resistance in cameroonian adults initiating antiretroviral therapy according to the world health organization guidelines 409
High Burden of HBV-Infection and Atypical HBV Strains among HIV-infected Cameroonians 408
Use of novel antiretroviral agents in rescue regimens: a case of early virological failure to raltegravir 405
Impact of pre-therapy viral load on virological response to modern first-line HAART 404
Reliability and clinical relevance of the HIV-1 drug resistance test in patients with low viremia levels 404
HIV-1 Genetic Variability and Clinical Implications 403
HIV-1 integrase genotyping is reliable and reproducible for routine clinical detection of integrase resistance mutations even in patients with low-level viraemia 401
Next-generation sequencing provides an added value in determining drug resistance and viral tropism in Cameroonian HIV-1 vertically infected children 400
Interpretation of genotypic HIV-1 resistance to darunavir and virological response: validation of available systems and of a new score 400
Genotypic tropism testing in HIV-1 proviral DNA can provide useful information at low-level viremia 399
Improved darunavir genotypic mutation score predicting treatment response for patients infected with HIRaben-1 subtype B and non-subtype B receiving a salvage regimen 395
Clinical relevance of genotypic resistance testing today 393
The genotypic false positive rate determined by V3 population sequencing can predict the burden of HIV-1 CXCR4-using species detected by pyrosequencing 390
Pre-existent NRTI and NNRTI resistance impacts on maintenance of virological suppression in HIV-1-infected patients who switch to a tenofovir/emtricitabine/rilpivirine single-tablet regimen 382
HIV-1 non-B subtypes in Italy: a growing trend 379
Dynamics and phylogenetic relationships of HIV-1 transmitted drug resistance according to subtype in Italy over the years 2000-14 376
Improving the prediction of virological response to tipranavir: the development and validation of a tipranavir-weighted mutation score 371
The Lowest X4 Geno2Pheno-False Positive Rate Is Associated with Greater CD4-Depletion 367
Integrase strand transfer inhibitor-based regimen is related with a limited HIV-1 V3 loop evolution in clinical practice 366
CEDRIC-HIV: la checklist per gli studi sulla resistenza ai farmaci anti-HIV 363
Impact of HIV-1 tropism on the emergence of non-AIDS events in HIV-infected patients receiving fully suppressive antiretroviral therapy 359
Rare occurrence of doravirine resistance-associated mutations in HIV-1-infected treatment-naive patients 359
Genetic divergence of HIV-1 B subtype in Italy over the years 2003–2016 and impact on CTL escape prevalence 356
The HIV-1 reverse transcriptase polymorphism A98S improves the response to tenofovir disoproxil fumarate + emtricitabine-containing HAART both in vivo and in vitro 326
Recent transmission clustering of HIV-1 C and CRF17-BF strains characterized by NNRTI-related mutations among newly diagnosed men in central Italy 319
Resistance detected in PBMCs predicts virological rebound in HIV-1 suppressed patients switching treatment 307
Quantification of HIV-DNA and residual viremia in patients starting ART by droplet digital PCR: Their dynamic decay and correlations with immunological parameters and virological success 307
Very high pre-therapy viral load is a predictor of virological rebound in HIV-1-infected patients starting a modern first-line regimen 304
Characterisation of HIV-1 molecular transmission clusters among newly diagnosed individuals infected with non-B subtypes in Italy 270
HIV MDR is still a relevant issue despite its dramatic drop over the years 249
New resistance mutations to nucleoside reverse transcriptase inhibitors at codon 184 of HIV-1 reverse transcriptase (M184L and M184T) 229
Evaluation of HIV-1 integrase resistance emergence and evolution in patients treated with integrase inhibitors 221
Is the rate of virological failure to cART continuing to decline in recent calendar years? 215
Current status of antivirals and druggable targets of SARS CoV-2 and other human pathogenic coronaviruses 214
Genetic diversity of HIV type 1 in Montenegro 207
Identification of gp120 polymorphisms in HIV-1 B subtype potentially associated with resistance to fostemsavir 207
Global epidemiology of drug resistance after failure of WHO recommended first-line regimens for adult HIV-1 infection: A multicentre retrospective cohort study 203
HIV-1 drug resistance testing is essential for heavily-treated patients switching from first- to second-line regimens in resource-limited settings: Evidence from routine clinical practice in Cameroon 195
Prevalence of doravirine-associated resistance mutations in HIV-1-infected antiretroviral-experienced patients from two large databases in France and Italy 187
Viral suppression in adults, adolescents and children receiving antiretroviral therapy in Cameroon: Adolescents at high risk of virological failure in the era of "test and treat" 180
Italian expert panel consensus statements on two-drug antiretroviral regimens to treat naïve and virologically suppressed HIV-1 infected patients 171
Comparison of Different HIV-1 Resistance Interpretation Tools for Next-Generation Sequencing in Italy 159
Frequency of atypical mutations in the spike glycoprotein in SARS-CoV-2 circulating from July 2020 to July 2022 in central Italy: a refined analysis by Next Generation Sequencing 156
Use of next-generation sequencing on HIV-1 DNA to assess archived resistance in highly treatment-experienced people with multidrug-resistant HIV under virological control: data from the PRESTIGIO Registry 151
Baseline integrase drug resistance mutations and conserved regions across HIV-1 clades in Cameroon: implications for transition to dolutegravir in resource-limited settings 142
HIV-1 transmitted drug resistance in newly diagnosed individuals in Italy over the period 2015-21 141
Genetic Determinants in a Critical Domain of NS5A Correlate with Hepatocellular Carcinoma in Cirrhotic Patients Infected with HCV Genotype 1b 138
Impact of analytical treatment interruption on burden and diversification of HIV peripheral reservoir: a pilot study 137
Mutational Correlates of Virological Failure in Individuals Receiving a WHO-Recommended Tenofovir-Containing First-Line Regimen: An International Collaboration 136
Viral resistance burden and APOBEC editing correlate with virological response in heavily treatment-experienced people living with multi-drug resistant HIV 131
Detection of Gag C-terminal mutations among HIV-1 non-B subtypes in a subset of Cameroonian patients 127
High performance of integrase genotyping on diverse HIV-1 clades circulating in Cameroon: toward a successful transition to dolutegravir-based regimens in low and middle-income countries 123
Managing low-level HIV viraemia in antiretroviral therapy: a systematic review and meta-analysis 119
Evaluation of virological response and resistance profile in HIV-1 infected patients starting a first-line integrase inhibitor-based regimen in clinical settings 115
Alarming rates of virological failure and HIV-1 drug resistance amongst adolescents living with perinatal HIV in both urban and rural settings: evidence from the EDCTP READY-study in Cameroon 113
Impact of transmitted HIV-1 drug resistance on the efficacy of firstline antiretroviral therapy with two nucleos(t)ide reverse transcriptase inhibitors plus an integrase inhibitor or a protease inhibitor 112
Susceptibility to HIV-1 integrase strand transfer inhibitors (INSTIs) in highly treatment-experienced patients who failed an INSTI-based regimen 109
Totale 35.303
Salva come PNG Salva come JPEG
Categoria #
all - tutte 114.631
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 114.631
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20221.345 56 76 83 49 59 91 54 37 346 129 57 308
2022/20231.684 170 137 87 178 159 348 113 168 137 37 102 48
2023/2024683 80 18 29 24 53 126 37 18 19 138 11 130
2024/20254.735 160 906 460 241 141 254 599 193 418 293 539 531
2025/20268.240 574 315 671 730 870 361 1.029 951 833 797 586 523
2026/2027282 282 0 0 0 0 0 0 0 0 0 0 0
Totale 41.217